Cargando…

Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response

The tremendous advances in understanding the neurobiological circuits involved in schizophrenia have not translated into more effective treatments. An alternative strategy is to use a recently published ‘Quantitative Systems Pharmacology’ computer-based mechanistic disease model of cortical/subcorti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geerts, Hugo, Spiros, Athan, Roberts, Patrick, Twyman, Roy, Alphs, Larry, Grace, Anthony A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522663/ https://www.ncbi.nlm.nih.gov/pubmed/23251349 http://dx.doi.org/10.1371/journal.pone.0049732

Ejemplares similares

A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance
por: Spiros, Athan, et al.
Publicado: (2014)

A biophysically realistic computer model of Alzheimer pathology to guide the development of symptomatic drugs
por: Roberts, Patrick D, et al.
Publicado: (2012)

Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
por: Roberts, Patrick D, et al.
Publicado: (2012)

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology
por: Geerts, Hugo, et al.
Publicado: (2015)

Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study
por: Spiros, Athan, et al.
Publicado: (2021)

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Spiros, Athan, et al.
Publicado: (2010)

A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease
por: Roberts, Patrick, et al.
Publicado: (2016)

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model
por: Geerts, Hugo, et al.
Publicado: (2018)

A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease
por: Geerts, Hugo, et al.
Publicado: (2013)

A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development
por: Spiros, Athan, et al.
Publicado: (2012)

F189. PERSONALIZED MEDICINE: ESTIMATING THE IMPACT OF GENOTYPES ON ANTIPSYCHOTIC EFFICACY USING A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
por: Geerts, Hugo, et al.
Publicado: (2018)

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach
por: Geerts, Hugo, et al.
Publicado: (2020)

A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia
por: Geerts, H, et al.
Publicado: (2013)

Has the Time Come for Predictive Computer Modeling in CNS Drug Discovery and Development?
por: Geerts, H, et al.
Publicado: (2012)

S221. QUANTITATIVE SYSTEMS PHARMACOLOGY AS AN ALTERNATIVE TO CHLORPROMAZINE EQUIVALENTS: PREDICTIVE VALIDATION FROM A CRIS DATABASE EXPERIMENT
por: Geerts, Hugo, et al.
Publicado: (2018)

Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2018)

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
por: Alphs, Larry, et al.
Publicado: (2011)

Prediction of Efficacy of Vabicaserin, a 5-HT(2C) Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model
por: Liu, J, et al.
Publicado: (2014)

Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia
por: Basu, Anirban, et al.
Publicado: (2018)

Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
por: Bossie, Cynthia A., et al.
Publicado: (2015)

Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
por: Alphs, Larry, et al.
Publicado: (2012)

Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization
por: Markowitz, Michael, et al.
Publicado: (2013)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa, Jennifer Kern, et al.
Publicado: (2012)

Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate
por: Sliwa, Jennifer Kern, et al.
Publicado: (2014)

Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
por: Levitan, Bennett, et al.
Publicado: (2016)

Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent‐onset versus more chronic schizophrenia and a history of criminal justice system involvement
por: Alphs, Larry, et al.
Publicado: (2015)

What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?
por: Kemp, Aaron S., et al.
Publicado: (2010)

Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial
por: Bossie, Cynthia A., et al.
Publicado: (2011)

Connectivity, Pharmacology, and Computation: Toward a Mechanistic Understanding of Neural System Dysfunction in Schizophrenia
por: Anticevic, Alan, et al.
Publicado: (2013)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial
por: Bossie, Cynthia A, et al.
Publicado: (2011)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

Base rates, blindness, and schizophrenia
por: Silverstein, Steven M., et al.
Publicado: (2013)

Mechanistic action of weak acid drugs on biofilms
por: Kundukad, Binu, et al.
Publicado: (2017)

A Mechanistic Account of Wide Computationalism
por: Kersten, Luke
Publicado: (2016)

Paper 18: Effect of Bone Marrow Aspirate Concentrate on Osteochondral Allograft Transplantation Incorporation: A Prospective, Randomized, Single Blind Investigation
por: Yanke, Adam, et al.
Publicado: (2022)

The Mechanistic Classification of Addictive Drugs
por: Lüscher, Christian, et al.
Publicado: (2006)

Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights
por: Gusev, Alexander, et al.
Publicado: (2018)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Corrigendum: Base Rates, Blindness, and Schizophrenia
por: Silverstein, Steven M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5jfpqnl89umjmgpe57sfdtuofn